ARS Pharmaceuticals, Inc.
NASDAQSPRY posted a 6% gain on the week to $6.30, but the real story is what's happening in the lending market — short interest remains near 22% of the free float, borrow availability is close to fully used, and the stock fell 6.6% the day after its most recent earnings print. The borrow picture is the sharpest signal right now. Availability has tightened dramatically over the past 30…
SPRY utilization hits 98.94%, near 52-week high of 100%, as shares available to borrow remain critically scarce at just 6.4% of short interest.
SPRY posted a 6% gain on the week to $6.30, but the real story is what's happening in the lending market — short interest remains near 22% of the free float, borrow availability is close to fully used, and the stock…
ARS Pharmaceuticals enters the post-Q1 period in a compressed vice: a quarterly earnings miss sent the stock down 6.5% on Friday to $7.43, while the lending market for its shares is as tight as it has been all…
Snapshot as of 29 Sept 2026
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SPRY — free to start on ORTEX.
Sign up for free →Open SPRY on ORTEX